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Analogues of luteinising hormone-releasing hormone
(LHRH) are very much in fashion. Their design is clever and
they offer an effective medical alternative to surgical castra-
tion in the treatment of breast and prostatic cancer. In breast
cancer their use in metastatic disease is increasing steadily,
and current enthusiasm is such that multicentre adjuvant
therapy trials in early disease are already under way. Yet
LHRH analogues are expensive (a year's supply of depot
Zoladex currently costs around £1,500) and other therapeutic
options are available. So how much do we really need them?
The hypothalamic decapeptide LHRH stimulates pituitary
gonadotrophin secretion to promote the peripheral release of
ovarian oestrogens or testicular androgens. A key to its
physiological function is its pulsatile release at intervals of
around 90 min. Modifications at the six and ten positions in
the decapeptide chain produce analogues with greater po-
tency and a longer half-life than the parent hormone. Init-
ially these analogues mimic LHRH with a brief surge in
gonadotrophin secretion, but continuous rather than pulsatile
exposure eventually down-regulates pituitary LHRH mem-
brane receptors. This leads to a paradoxical inhibition of
gonadotrophin release and a consequent marked fall in
plasma oestrogens to castration levels (Harvey et al., 1985;
Williams et al., 1986). In striking contrast to surgical castra-
tion, the effect is entirely reversible on stopping treatment.
The therapeutic possibilities for LHRH analogues in the
treatment of breast cancer were quickly apparent. Experi-
mentally they cause regression of oestrogen dependent
DMBA-induced rat mammary tumours (Nicolson & May-
nard, 1979). In the clinic, the analogues goserelin (Zoladex,
ICI), buserelin and leuprorelin have all been shown to sup-
press plasma oestrogens within 2-3 weeks of starting treat-
ment and to achieve clinical regression of metastatic breast
cancer in premenopausal women (Klijn, 1984; Harvey et al.,
1985; Williams et al., 1986). Initially, formulation was a
problem. LHRH and its analogues are small peptides suscep-
tible to alimentary tract digestion and therefore unsuitable
for oral use. Early clinical studies therefore used daily sub-
cutaneous or intra-muscular injection, and buserelin has been
marketed as a nasal spray. Absorption from buccal and
vaginal mucosa has also been investigated. More recently
monthly depot preparations have become available for gos-
erelin and leuprorelin, and this has greatly simplified admini-
stration.
LHRH analogues have also been investigated in post-
menopausal women. On the fact of it, this might seem as
illogical as oophorectomy itself. However, buserelin has been
reported as having direct inhibitory effects on a human
breast cancer cell line in vitro (Miller et al., 1985), and low
affinity LHRH binding sites have been shown both in this
cell line and in 20 out of 30 fresh breast cancer specimens
(Eidne et al., 1985). Some clinical studies have reported
occasional objective responses in postmenopausal women
(Plowman et al., 1986; Harris et al., 1989), but other groups
including ourselves have found no significant clinical activity
(Waxman et al., 1985; Crighton et al., 1989). The clinical
effects of LHRH analogues in postmenopausal women there-
fore appear to be small and probably unimportant compared
with other forms of endocrine therapy.
In a recent edition of the British Journal of Cancer, results
from one of the first clinical studies were updated (Dixon et
al., 1990). Seventy-five premenopausal patients with metastatic
breast cancer were treated with monthly depot goserelin.
Thirty-three per cent achieved an objective tumour response
with a median response duration of greater than 15 months;
response predictably correlated with positive ER status, and
apart from menopausal symptoms no significant side-effects
were seen. Other groups have confirmed these results, both
with depot goserelin (Kaufman et al., 1989) and depot leu-
prorelin, where our own results currently show a 35% res-
ponse rate. With this experience in metastatic disease, multi-
centre adjuvant trials in premenopausal early breast cancer
are now underway: a UK CRC trial is comparing goserelin
(Zoladex) with tamoxifen and with both in combination, and
a European trial is about to compare goserelin with CMF
chemotherapy.
Dixon and his colleagues conclude from their study that
there is no current role for surgical oophorectomy in the
management of premenopausal patients with metastatic
breast cancer, and they are almost certainly right. Results
with LHRH analogues appear just as good as those achieved
in the past with oophorectomy; two randomised comparative
trials are underway for the purists, but accrual is slow and
this probably reflects the increasing unattractiveness of the
oophorectomy option.
But the real point here is in danger of being missed.
Oophorectomy is already a redundant treatment whether or
not LHRH analogues are effective, and it is redundant
because of tamoxifen. Reservations are sometimes expressed
about tamoxifen in premenopausal women because it raises
plasma oestradiol and does not always achieve amenorrhoea.
Yet two randomised trials have shown that this is of no
clinical consequence whatever: tamoxifen is as effective as
oophorectomy in every respect and with minimal toxicity
(Buchanan et al., 1986; Ingle et al., 1986). Indeed, the failure
of tamoxifen to achieve postmenopausal oestrogen levels is
probably a positive benefit rather than a disadvantage; unlike
oophorectomy (and presumably LHR analogues) it does not
appear to cause bone demineralisation, and it significantly
lowers serum cholesterol and low density lipoproteins (Pow-
les et al., 1990).
The real test for the LHRH analogues is no longer against
oophorectomy, but against tamoxifen. Are they more
effective? Are they in any way better tolerated? How do their
long term effects on bone demineralisation and plasma lipids
compare? As with so many other new forms of breast cancer
treatment, tamoxifen is still the one to beat.
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